<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605785</url>
  </required_header>
  <id_info>
    <org_study_id>15-004618</org_study_id>
    <nct_id>NCT02605785</nct_id>
  </id_info>
  <brief_title>A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy</brief_title>
  <official_title>A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to learn more about overall tau burden in the brain of patients with&#xD;
      Progressive Supranuclear Palsy (PSP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The investigators will be looking at the amount of Tau protein in the brain of patients with PSP.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of change in tau-PET burden over time.</measure>
    <time_frame>baseline, 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>Tau PET Scan, F-18 AV 1451</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will received a Tau PET scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18 AV 1451</intervention_name>
    <description>Tau PET scan</description>
    <arm_group_label>Tau PET Scan, F-18 AV 1451</arm_group_label>
    <other_name>Tau binding agent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be over 35 years of age and present with gradual progression of PSP-related&#xD;
             symtoms&#xD;
&#xD;
          -  Must have an informant or study partner that can provide independent information of&#xD;
             functioning.&#xD;
&#xD;
          -  Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill&#xD;
             criteria for possible PSP, subjects must have a gradually progressive disorder with&#xD;
             either vertical (upward or downward) supranuclear palsy or both slowing of vertical&#xD;
             saccades and prominent postural instability with falls in the first year of disease&#xD;
             onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or&#xD;
             downward gaze) supranuclear palsy and prominent postural instability with falls in the&#xD;
             first year of disease onset.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded if they meet criteria for another neurodegenerative disease&#xD;
             (including corticobasal syndrome, frontotemporal dementia, primary progressive&#xD;
             aphasia, Alzheimer's disease, multiple system atrophy and Parkinson's disease) or do&#xD;
             not have the symptoms necessary to fulfill inclusion criteria for possible PSP.&#xD;
&#xD;
          -  Subjects with concurrent illnesses that could account for their symptoms, such as&#xD;
             traumatic brain injury, encephalitis, strokes or developmental syndromes will be&#xD;
             excluded.&#xD;
&#xD;
          -  Women that are pregnant or post-partum and breast-feeding will be excluded.&#xD;
&#xD;
          -  Subjects will be excluded from the study if they have any of the following genetic&#xD;
             conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome,&#xD;
             hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome.&#xD;
&#xD;
          -  Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace&#xD;
             maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may&#xD;
             confound brain imaging studies (e.g. structural abnormalities, including subdural&#xD;
             hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically&#xD;
             unstable or are on medications that might affect brain structure or metabolism (e.g.&#xD;
             chemotherapy).&#xD;
&#xD;
          -  Subjects will also be excluded if they do not have an informant, or do not consent to&#xD;
             research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Josephs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah M Boland, CCRP</last_name>
    <phone>507-284-3863</phone>
    <email>boland.sarah@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah M Boland, CCRP</last_name>
      <phone>507-284-3863</phone>
      <email>boland.sarah@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Keith Josephs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Keith A. Josephs</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>PSP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

